Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    10075741 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: Dasatinib

Indicates status has not been verified in more than two years